title: Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
abstract: Treatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while many studies have reported on gefitinib-related interstitial lung disease (ILD), less published data are available regarding erlotinib-induced ILD. Here, we report a case of pulmonary adenocarcinoma who developed ILD due to gefitinib initially and erlotinib thereafter. The two episodes of ILD were treated successfully with the discontinuation of the tyrosine kinase inhibitors and high-dose intravenous corticosteroids.
authors.affiliation: Department of Internal Medicine, National Yang-Ming University Hospital, Yilan, Taiwan, ROC.
authors.forename: Ko-Fan
authors.initials: KF
authors.lastname: Wang
authors.forename: Cheng-Yu
authors.initials: CY
authors.lastname: Chang
authors.forename: Shih-Chieh
authors.initials: SC
authors.lastname: Chang
authors.forename: Yu-Chang
authors.initials: YC
authors.lastname: Liu
authors.forename: Mei-Kang
authors.initials: MK
authors.lastname: Yuan
authors.forename: Yuan-Hao
authors.initials: YH
authors.lastname: Yang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib